$AQST News

Aquestive Therapeutics Files Prospectus For Offering 230,271 Common Shares On Behalf Of Selling Shareholders

Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

Aquestive Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript

Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $48.072M Est

Aquestive Therapeutics Q1 EPS $(0.07) Beats $(0.15) Estimate, Sales $14.446M Beat $10.896M Estimate

Aquestive Therapeutics Reaffirms Guidance To Resubmit The Anaphylm NDA In Q3 2026; Final FDA Meeting Minutes Expected By Early May 2026

Aquestive Therapeutics Completes In-Person Type A Meeting With FDA Regarding Resubmission Of NDA For Anaphylm Sublingual Film For Treatment Of Type 1 Allergic Reactions, Including Anaphylaxis

Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation

Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval

Aquestive Therapeutics Q4 Earnings Call Highlights

Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ...

Aquestive Therapeutics, Inc. Q4 2025 Earnings Call Summary

Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript

Aquestive Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics

Aquestive Therapeutics Inc (NASDAQ:AQST) Reports Mixed Q4 2025 Results and Anaphylm Regulatory Update

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

Aquestive Therapeutics: Q4 Earnings Snapshot